QQQ   303.46 (-0.04%)
AAPL   151.23 (-0.33%)
MSFT   260.06 (+1.28%)
META   186.04 (-0.01%)
GOOGL   103.00 (+0.10%)
AMZN   101.84 (-0.33%)
TSLA   196.00 (+0.64%)
NVDA   212.64 (+0.83%)
NIO   11.00 (+0.64%)
BABA   106.70 (+1.19%)
AMD   84.26 (+0.69%)
T   19.54 (-0.20%)
F   13.10 (-0.30%)
MU   60.00 (+0.03%)
CGC   2.94 (-0.34%)
GE   82.28 (-0.09%)
DIS   109.86 (+-0.01%)
AMC   6.94 (+2.06%)
PFE   43.98 (+0.50%)
PYPL   82.30 (-0.04%)
NFLX   359.86 (-0.45%)
QQQ   303.46 (-0.04%)
AAPL   151.23 (-0.33%)
MSFT   260.06 (+1.28%)
META   186.04 (-0.01%)
GOOGL   103.00 (+0.10%)
AMZN   101.84 (-0.33%)
TSLA   196.00 (+0.64%)
NVDA   212.64 (+0.83%)
NIO   11.00 (+0.64%)
BABA   106.70 (+1.19%)
AMD   84.26 (+0.69%)
T   19.54 (-0.20%)
F   13.10 (-0.30%)
MU   60.00 (+0.03%)
CGC   2.94 (-0.34%)
GE   82.28 (-0.09%)
DIS   109.86 (+-0.01%)
AMC   6.94 (+2.06%)
PFE   43.98 (+0.50%)
PYPL   82.30 (-0.04%)
NFLX   359.86 (-0.45%)
QQQ   303.46 (-0.04%)
AAPL   151.23 (-0.33%)
MSFT   260.06 (+1.28%)
META   186.04 (-0.01%)
GOOGL   103.00 (+0.10%)
AMZN   101.84 (-0.33%)
TSLA   196.00 (+0.64%)
NVDA   212.64 (+0.83%)
NIO   11.00 (+0.64%)
BABA   106.70 (+1.19%)
AMD   84.26 (+0.69%)
T   19.54 (-0.20%)
F   13.10 (-0.30%)
MU   60.00 (+0.03%)
CGC   2.94 (-0.34%)
GE   82.28 (-0.09%)
DIS   109.86 (+-0.01%)
AMC   6.94 (+2.06%)
PFE   43.98 (+0.50%)
PYPL   82.30 (-0.04%)
NFLX   359.86 (-0.45%)
QQQ   303.46 (-0.04%)
AAPL   151.23 (-0.33%)
MSFT   260.06 (+1.28%)
META   186.04 (-0.01%)
GOOGL   103.00 (+0.10%)
AMZN   101.84 (-0.33%)
TSLA   196.00 (+0.64%)
NVDA   212.64 (+0.83%)
NIO   11.00 (+0.64%)
BABA   106.70 (+1.19%)
AMD   84.26 (+0.69%)
T   19.54 (-0.20%)
F   13.10 (-0.30%)
MU   60.00 (+0.03%)
CGC   2.94 (-0.34%)
GE   82.28 (-0.09%)
DIS   109.86 (+-0.01%)
AMC   6.94 (+2.06%)
PFE   43.98 (+0.50%)
PYPL   82.30 (-0.04%)
NFLX   359.86 (-0.45%)
NASDAQ:GRTS

Gritstone bio - GRTS Stock Forecast, Price & News

$3.16
-0.02 (-0.63%)
(As of 02/7/2023 09:26 AM ET)
Add
Compare
Today's Range
$3.16
$3.19
50-Day Range
$2.58
$3.92
52-Week Range
$1.71
$6.10
Volume
3,603 shs
Average Volume
692,320 shs
Market Capitalization
$263.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Gritstone bio MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
57.2% Upside
$5.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.36) to ($1.29) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.59 out of 5 stars

Medical Sector

837th out of 1,027 stocks

Biological Products, Except Diagnostic Industry

135th out of 169 stocks

GRTS stock logo

About Gritstone bio (NASDAQ:GRTS) Stock

Gritstone bio, Inc. clinical-stage biotechnology company, which engages in developing the next generation of cancer immunotherapies to fight multiple cancer types. The company was founded by Andrew Allen, Timothy Chan, Mark Cobbold, Graham Lord, Naiyer Rizvi and Jean-Charles Soria in August 2015 and is headquartered in Emeryville, CA.

Receive GRTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gritstone bio and its competitors with MarketBeat's FREE daily newsletter.

GRTS Stock News Headlines

GRAPHITE: "Essential for America's National Defense"
Did you know each EV battery contains up to 220 pounds of graphite and China controls more than 90% of the world's graphite trade? But now that the U.S. has classified it as "essential for America's National Defense"... one little-known company could become America's ONLY fully integrated graphite provider.
Solar Industry at Start of Long Bull Run?
The U.S. solar industry generated nearly $33 billion of private investment in the American economy in 2021 -- and analysts say it looks like the start of a long solar bull market. Leading the way is the just-signed Inflation Reduction Act of 2022. With its generous investment tax credits, the Act is expected to triple U.S. solar energy production over the next 5 years.
Gritstone Shares Jump Over 14% on mRNA Patent News
Gritstone to Participate in Upcoming Investor Conferences
Gritstone bio, Inc. (GRTS)
See More Headlines
Receive GRTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gritstone bio and its competitors with MarketBeat's FREE daily newsletter.

GRTS Company Calendar

Last Earnings
11/02/2021
Today
2/07/2023
Next Earnings (Estimated)
3/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GRTS
Fax
N/A
Employees
193
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.00
High Stock Price Forecast
$7.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+58.2%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-75,080,000.00
Net Margins
-630.32%
Pretax Margin
-630.32%

Debt

Sales & Book Value

Annual Sales
$48.21 million
Book Value
$3.18 per share

Miscellaneous

Free Float
79,640,000
Market Cap
$263.45 million
Optionable
Not Optionable
Beta
0.47

Key Executives

  • Andrew R. Allen
    President, Chief Executive Officer & Director
  • Erin E. JonesErin E. Jones
    Chief Operating Officer & Executive Vice President
  • Vassiliki Celia Economides
    Chief Financial Officer & Executive Vice President
  • Karin Jooss
    Executive VP & Head-Research & Development
  • Matthew J. Hawryluk
    Chief Business Officer & Executive Vice President













GRTS Stock - Frequently Asked Questions

Should I buy or sell Gritstone bio stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Gritstone bio in the last twelve months. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GRTS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GRTS, but not buy additional shares or sell existing shares.
View GRTS analyst ratings
or view top-rated stocks.

What is Gritstone bio's stock price forecast for 2023?

3 brokers have issued twelve-month target prices for Gritstone bio's shares. Their GRTS share price forecasts range from $2.00 to $7.00. On average, they expect the company's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 57.2% from the stock's current price.
View analysts price targets for GRTS
or view top-rated stocks among Wall Street analysts.

How have GRTS shares performed in 2023?

Gritstone bio's stock was trading at $3.45 at the beginning of the year. Since then, GRTS shares have decreased by 7.8% and is now trading at $3.18.
View the best growth stocks for 2023 here
.

When is Gritstone bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023.
View our GRTS earnings forecast
.

How were Gritstone bio's earnings last quarter?

Gritstone bio, Inc. (NASDAQ:GRTS) released its quarterly earnings results on Tuesday, November, 2nd. The company reported ($0.36) earnings per share for the quarter, topping analysts' consensus estimates of ($0.52) by $0.16. The firm earned $2.61 million during the quarter, compared to analysts' expectations of $3 million. Gritstone bio had a negative trailing twelve-month return on equity of 67.00% and a negative net margin of 630.32%.

What is Andrew Allen's approval rating as Gritstone bio's CEO?

1 employees have rated Gritstone bio Chief Executive Officer Andrew Allen on Glassdoor.com. Andrew Allen has an approval rating of 100% among the company's employees. This puts Andrew Allen in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Gritstone bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Gritstone bio investors own include ADMA Biologics (ADMA), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Novan (NOVN), Sorrento Therapeutics (SRNE), Zosano Pharma (ZSAN), Enerplus (ERF), Oncolytics Biotech (ONCY), SCYNEXIS (SCYX) and CBL & Associates Properties (CBL).

When did Gritstone bio IPO?

(GRTS) raised $85 million in an initial public offering on Friday, September 28th 2018. The company issued 6,100,000 shares at $13.00-$15.00 per share. Goldman Sachs, Cowen and Barclays acted as the underwriters for the IPO and BTIG was co-manager.

What is Gritstone bio's stock symbol?

Gritstone bio trades on the NASDAQ under the ticker symbol "GRTS."

Who are Gritstone bio's major shareholders?

Gritstone bio's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Frazier Life Sciences Management L.P. (6.19%), Assenagon Asset Management S.A. (2.33%), SkyOak Wealth LLC (0.16%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Erin Jones and Raphael Rousseau.
View institutional ownership trends
.

How do I buy shares of Gritstone bio?

Shares of GRTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Gritstone bio's stock price today?

One share of GRTS stock can currently be purchased for approximately $3.18.

How much money does Gritstone bio make?

Gritstone bio (NASDAQ:GRTS) has a market capitalization of $265.12 million and generates $48.21 million in revenue each year. The company earns $-75,080,000.00 in net income (profit) each year or ($1.39) on an earnings per share basis.

How many employees does Gritstone bio have?

The company employs 193 workers across the globe.

How can I contact Gritstone bio?

Gritstone bio's mailing address is 5858 HORTON STREET SUITE 210, EMERYVILLE CA, 94608. The official website for the company is www.gritstoneoncology.com. The company can be reached via phone at (510) 871-6100 or via email at ir@gritstone.com.

This page (NASDAQ:GRTS) was last updated on 2/7/2023 by MarketBeat.com Staff